Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Fineline Cube May 18, 2026
Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Fineline Cube May 18, 2026
Company Deals

Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million

Fineline Cube Feb 10, 2026

Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH) has entered a strategic licensing agreement with...

Company Deals

Henlius Biotech Secures Global Rights to U-mab’s IL-1RAP Antibody in Licensing Deal

Fineline Cube Feb 10, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced a licensing agreement with U-mab Biopharma, acquiring exclusive...

Company Deals

Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million

Fineline Cube Feb 10, 2026

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has entered a strategic licensing agreement with Qilu...

Company Deals

Kintor Pharma Signs Exclusive China Distribution Deal for Anti-Hair Loss Foam with Dekai Med

Fineline Cube Feb 10, 2026

Kintor Pharmaceutical Limited (HKG: 9939) has entered an exclusive marketing service agreement with Beijing Dekai...

Company Deals Drug

Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage

Fineline Cube Feb 10, 2026

Huadong Medicine Co., Ltd (SHE: 000963) announced a key milestone in its strategic collaboration with...

Company Deals

Bao Pharma Partners with Shanghai RAAS to Develop Subcutaneous Blood Products Using Hyaluronidase Technology

Fineline Cube Feb 10, 2026

Shanghai Bao Pharmaceuticals Co., Ltd. (HKG: 2659) has entered a strategic partnership with Shanghai RAAS...

Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Fineline Cube Feb 9, 2026

Delonix Bioworks announced that DX-104, its Group B meningococcal (MenB) vaccine candidate, has received clinical...

Company Medical Device

Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market

Fineline Cube Feb 9, 2026

Peijia Medical Ltd (HKG: 9996) announced it has submitted CE mark registration under the European...

Company

Novartis Breaks Ground on $23 Billion US Biomedical Research Center in San Diego

Fineline Cube Feb 9, 2026

Novartis AG (NYSE: NVS) held a groundbreaking ceremony for a state-of-the-art global biomedical research center...

Company Drug

Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer

Fineline Cube Feb 9, 2026

Sino Biopharmaceutical Ltd (HKG: 1177) announced completion of patient enrollment for the registrational Phase III...

Company Drug

Gilead’s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma

Fineline Cube Feb 9, 2026

Kite Pharma, a Gilead Sciences (NASDAQ: GILD) subsidiary, announced that the U.S. Food and Drug...

Company Medical Device

Jenscare Scientific’s LuX-Valve Plus Wins FDA Nod for US Pivotal Trial in Tricuspid Regurgitation

Fineline Cube Feb 9, 2026

Jenscare Scientific Co., Ltd. (HKG: 9877) announced that the U.S. Food and Drug Administration (FDA)...

Company Drug

Hengrui Pharma’s HRS-4642 Wins Breakthrough Therapy Designation for KRAS G12D Pancreatic Cancer

Fineline Cube Feb 9, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS-4642, its KRAS G12D-targeting...

Company Drug

Pfizer’s Hympavzi Wins FDA Priority Review for Pediatric Hemophilia Expansion

Fineline Cube Feb 9, 2026

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted...

Company Drug

Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials

Fineline Cube Feb 9, 2026

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced positive top-line results from two Phase III...

Company Drug

InnoCare Pharma’s ICP-538 Becomes First VAV1 Molecular Glue Degrader to Enter China Clinical Trials

Fineline Cube Feb 9, 2026

InnoCare Pharma Limited (SHA: 688428, HKG: 9969) announced that its self-developed VAV1-targeting molecular glue degrader,...

Company Drug

Betta Pharma Secures NMPA Approval for Beizeting, First Domestic Pertuzumab Biosimilar in China

Fineline Cube Feb 9, 2026

Betta Pharmaceuticals Co., Ltd. (SHE: 300558) announced that the National Medical Products Administration (NMPA) has...

Company Drug

Kelun-Biotech’s Jiatailai Secures Fourth NMPA Approval for HR+/HER2- Breast Cancer Indication

Fineline Cube Feb 9, 2026

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that the National Medical Products Administration (NMPA)...

Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026

The Medical Products Administration of Guangdong Province (GDMPA) and Health Commission of Guangdong Province (GDHC)...

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026

Insight Lifetech, a Qiming Venture Partners‑backed innovative medical device manufacturer, has listed on the Shanghai...

Posts pagination

1 … 45 46 47 … 667

Recent updates

  • AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting
  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
  • AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data
  • Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.